CN114127051A - 成纤维细胞生长因子受体激酶的抑制剂 - Google Patents

成纤维细胞生长因子受体激酶的抑制剂 Download PDF

Info

Publication number
CN114127051A
CN114127051A CN202080051864.XA CN202080051864A CN114127051A CN 114127051 A CN114127051 A CN 114127051A CN 202080051864 A CN202080051864 A CN 202080051864A CN 114127051 A CN114127051 A CN 114127051A
Authority
CN
China
Prior art keywords
optionally substituted
pharmaceutically acceptable
solvate
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051864.XA
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·W·卡尔多
约翰·泰霍纳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinnaite Biopharmaceutical Co
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN114127051A publication Critical patent/CN114127051A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080051864.XA 2019-05-17 2020-05-14 成纤维细胞生长因子受体激酶的抑制剂 Pending CN114127051A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849534P 2019-05-17 2019-05-17
US62/849,534 2019-05-17
US201962907491P 2019-09-27 2019-09-27
US62/907,491 2019-09-27
PCT/US2020/032939 WO2020236524A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Publications (1)

Publication Number Publication Date
CN114127051A true CN114127051A (zh) 2022-03-01

Family

ID=73458745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051864.XA Pending CN114127051A (zh) 2019-05-17 2020-05-14 成纤维细胞生长因子受体激酶的抑制剂

Country Status (7)

Country Link
US (1) US20230174535A1 (https=)
EP (1) EP3969442A4 (https=)
JP (1) JP2022533939A (https=)
CN (1) CN114127051A (https=)
AU (1) AU2020278566A1 (https=)
CA (1) CA3139161A1 (https=)
WO (1) WO2020236524A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4161657A1 (en) * 2020-06-05 2023-04-12 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
IL298760A (en) 2020-06-05 2023-02-01 Kinnate Biopharma Inc Fibroblast growth factor receptor kinase inhibitors
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407440A1 (en) * 2021-12-08 2024-06-20 Kinnate Biopharma Inc. Solid state forms of an fgfr inhibitor
WO2025024665A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Treatment of cancer with a cdk inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN107406455A (zh) * 2015-03-31 2017-11-28 大鹏药品工业株式会社 3,5‑二取代的苯炔基化合物晶体
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI378934B (en) * 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
KR101461680B1 (ko) * 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
GB201503590D0 (en) * 2015-03-03 2015-04-15 Davis Adrian Topical formulation
WO2017139509A1 (en) * 2016-02-12 2017-08-17 Purdue Research Foundation Manipulating 3d virtual objects using hand-held controllers
US10685111B2 (en) * 2016-10-31 2020-06-16 Crowdstrike, Inc. File-modifying malware detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN107406455A (zh) * 2015-03-31 2017-11-28 大鹏药品工业株式会社 3,5‑二取代的苯炔基化合物晶体
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用

Also Published As

Publication number Publication date
JP2022533939A (ja) 2022-07-27
WO2020236524A1 (en) 2020-11-26
CA3139161A1 (en) 2020-11-26
AU2020278566A1 (en) 2021-12-23
EP3969442A1 (en) 2022-03-23
EP3969442A4 (en) 2023-08-02
US20230174535A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CN114127051A (zh) 成纤维细胞生长因子受体激酶的抑制剂
US11667634B2 (en) Inhibitors of RAF kinases
CN101084217B (zh) 作为治疗性化合物的咪唑并[4,5-b]吡啶-2-酮和唑并[4,5-b]吡啶-2-酮化合物及其类似物
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
CN113874381A (zh) Raf激酶的抑制剂
US11814384B2 (en) Inhibtors of Raf kinases
TW202229269A (zh) Raf激酶抑制劑
TW202409036A (zh) Parg抑制劑
AU2021285974A1 (en) Inhibitors of fibroblast growth factor receptor kinases
TW202342018A (zh) Mek激酶抑制劑
JP2024500636A (ja) ベンゼンスルホンアミド誘導体およびその使用
CN119403803A (zh) Parg抑制剂
CN118974039A (zh) 新型苯并噻吩衍生物及其作为bet抑制剂的用途
WO2023107870A1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN116438179B (zh) 作为ret激酶抑制剂的吡唑衍生物
HK40064672A (en) Inhibitors of fibroblast growth factor receptor kinases
WO2023070053A1 (en) Inhibitors of raf kinases
CN118439991B (zh) 一类rbj小分子抑制剂
HK40114068A (zh) Raf激酶的抑制剂
WO2025032214A1 (en) Indazole compounds and azaindazole compounds as inhibitors of raf kinases
HK40063842A (en) Inhibitors of raf kinases
WO2025054260A1 (en) Inhibitors of mek kinase
HK40061750A (en) Inhibitors of raf kinases
HK1153477A (en) Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064672

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301